Rethinking biotech investment and innovation in a productivity-driven era
Why now
Thesis: Long-run biotech thesis piece, no near catalyst
Catalyst to watch: R&D productivity data or FDA approvals
Main risk: Opinion piece with no hard data
Why it matters
Biotech investment framing around productivity is thematic commentary, not a tradeable catalyst.
Sources
- googlenews · news.google.com · 2026-09-28 10:04 UTC
- googlenews · news.google.com · 2026-09-28 10:04 UTC